Literature DB >> 19542471

Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice.

Caroline M Percopo1, Zhijun Qiu, Simon Phipps, Paul S Foster, Joseph B Domachowske, Helene F Rosenberg.   

Abstract

Enhanced disease is the term used to describe the aberrant Th2-skewed responses to naturally acquired human respiratory syncytial virus (hRSV) infection observed in individuals vaccinated with formalin-inactivated viral Ags. Here we explore this paradigm with pneumonia virus of mice (PVM), a pathogen that faithfully reproduces features of severe hRSV infection in a rodent host. We demonstrate that PVM infection in mice vaccinated with formalin-inactivated Ags from PVM-infected cells (PVM Ags) yields Th2-skewed hypersensitivity, analogous to that observed in response to hRSV. Specifically, we detect elevated levels of IL-4, IL-5, IL-13, and eosinophils in bronchoalveolar lavage fluid of PVM-infected mice that were vaccinated with PVM Ags, but not among mice vaccinated with formalin-inactivated Ags from uninfected cells (control Ags). Interestingly, infection in PVM Ag-vaccinated mice was associated with a approximately 10-fold reduction in lung virus titer and protection against weight loss when compared with infected mice vaccinated with control Ags, despite the absence of serum-neutralizing Abs. Given recent findings documenting a role for eosinophils in promoting clearance of hRSV in vivo, we explored the role of eosinophils in altering the pathogenesis of disease with eosinophil-deficient mice. We found that eosinophil deficiency had no impact on virus titer in PVM Ag-vaccinated mice, nor on weight loss or levels of CCL11 (eotaxin-1), IFN-gamma, IL-5, or IL-13 in bronchoalveolar lavage fluid. However, levels of both IL-4 and CCL3 (macrophage inflammatory protein-1alpha) in bronchoalveolar lavage fluid were markedly diminished in PVM Ag-vaccinated, PVM-infected eosinophil-deficient mice when compared with wild-type controls.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542471      PMCID: PMC2754814          DOI: 10.4049/jimmunol.0802270

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

Review 1.  Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity.

Authors:  B F Gibbs
Journal:  Clin Exp Med       Date:  2005-07       Impact factor: 3.984

2.  Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody.

Authors:  F P Polack; P G Auwaerter; S H Lee; H C Nousari; A Valsamakis; K M Leiferman; A Diwan; R J Adams; D E Griffin
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

3.  Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.

Authors:  T R Johnson; B S Graham
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 4.  Immune responses and disease enhancement during respiratory syncytial virus infection.

Authors:  Peter J M Openshaw; John S Tregoning
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

5.  Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Authors:  Robert B Belshe; Frances K Newman; Edwin L Anderson; Peter F Wright; Ruth A Karron; Sharon Tollefson; Frederick W Henderson; H Cody Meissner; Shabir Madhi; Don Roberton; Helen Marshall; Richard Loh; Peter Sly; Brian Murphy; Joanne M Tatem; Valerie Randolph; Jill Hackell; William Gruber; Theodore F Tsai
Journal:  J Infect Dis       Date:  2004-11-08       Impact factor: 5.226

Review 6.  Animal models for studying respiratory syncytial virus infection and its long term effects on lung function.

Authors:  Joseph B Domachowske; Cynthia A Bonville; Helene F Rosenberg
Journal:  Pediatr Infect Dis J       Date:  2004-11       Impact factor: 2.129

7.  Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Authors:  Ruth A Karron; Peter F Wright; Robert B Belshe; Bhagvanji Thumar; Roberta Casey; Frances Newman; Fernando P Polack; Valerie B Randolph; Anne Deatly; Jill Hackell; William Gruber; Brian R Murphy; Peter L Collins
Journal:  J Infect Dis       Date:  2005-03-01       Impact factor: 5.226

8.  Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.

Authors:  Sonya L Cyr; Taff Jones; Ioana Stoica-Popescu; Angela Brewer; Sophie Chabot; Michelle Lussier; David Burt; Brian J Ward
Journal:  Vaccine       Date:  2007-05-24       Impact factor: 3.641

9.  Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6.

Authors:  Kimberly D Dyer; Caroline M Percopo; Elizabeth R Fischer; Stanislaw J Gabryszewski; Helene F Rosenberg
Journal:  Blood       Date:  2009-08-03       Impact factor: 22.113

10.  Efficient replication of pneumonia virus of mice (PVM) in a mouse macrophage cell line.

Authors:  Kimberly D Dyer; Ingrid Mm Schellens; Cynthia A Bonville; Brittany V Martin; Joseph B Domachowske; Helene F Rosenberg
Journal:  Virol J       Date:  2007-06-04       Impact factor: 4.099

View more
  15 in total

1.  Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.

Authors:  Naoko Iwata-Yoshikawa; Akihiko Uda; Tadaki Suzuki; Yasuko Tsunetsugu-Yokota; Yuko Sato; Shigeru Morikawa; Masato Tashiro; Tetsutaro Sata; Hideki Hasegawa; Noriyo Nagata
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

2.  Canine pneumovirus replicates in mouse lung tissue and elicits inflammatory pathology.

Authors:  Caroline M Percopo; Edward J Dubovi; Randall W Renshaw; Kimberly D Dyer; Joseph B Domachowske; Helene F Rosenberg
Journal:  Virology       Date:  2011-05-20       Impact factor: 3.616

3.  Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway.

Authors:  Sophia Davidson; Gerard Kaiko; Zhixuan Loh; Amit Lalwani; Vivian Zhang; Kirsten Spann; Shen Yun Foo; Nicole Hansbro; Satoshi Uematsu; Shizuo Akira; Klaus I Matthaei; Helene F Rosenberg; Paul S Foster; Simon Phipps
Journal:  J Immunol       Date:  2011-04-11       Impact factor: 5.422

4.  A gammaherpesvirus licenses CD8 T cells to protect the host from pneumovirus-induced immunopathologies.

Authors:  Bénédicte Machiels; Laurent Gillet; Mickaël Dourcy; Céline Maquet; Lorène Dams; Gautier Gilliaux; Justine Javaux; Daniel Desmecht; Matthias Mack; Benjamin G Dewals
Journal:  Mucosal Immunol       Date:  2020-05-18       Impact factor: 7.313

Review 5.  Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red".

Authors:  James J Lee; Elizabeth A Jacobsen; Sergei I Ochkur; Michael P McGarry; Rachel M Condjella; Alfred D Doyle; Huijun Luo; Katie R Zellner; Cheryl A Protheroe; Lian Willetts; William E Lesuer; Dana C Colbert; Richard A Helmers; Paige Lacy; Redwan Moqbel; Nancy A Lee
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

6.  Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection.

Authors:  Stanislaw J Gabryszewski; Ofir Bachar; Kimberly D Dyer; Caroline M Percopo; Kristin E Killoran; Joseph B Domachowske; Helene F Rosenberg
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

7.  IL-21 promotes the pathologic immune response to pneumovirus infection.

Authors:  Rosanne Spolski; Lu Wang; Chi-Keung Wan; Cynthia A Bonville; Joseph B Domachowske; Hyoung-Pyo Kim; Zuxi Yu; Warren J Leonard
Journal:  J Immunol       Date:  2012-01-11       Impact factor: 5.422

Review 8.  Type 2 immunity in tissue repair and fibrosis.

Authors:  Richard L Gieseck; Mark S Wilson; Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

9.  Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6.

Authors:  Kimberly D Dyer; Caroline M Percopo; Elizabeth R Fischer; Stanislaw J Gabryszewski; Helene F Rosenberg
Journal:  Blood       Date:  2009-08-03       Impact factor: 22.113

10.  Pre-existing virus-specific CD8(+) T-cells provide protection against pneumovirus-induced disease in mice.

Authors:  Mary J G van Helden; Peter J S van Kooten; Cornelis P J Bekker; Andrea Gröne; David J Topham; Andrew J Easton; Claire J P Boog; Dirk H Busch; Dietmar M W Zaiss; Alice J A M Sijts
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.